Molika Ashford

Investigators highlighted data from efforts in breast and bladder cancer, demonstrating that the company's platform could help oncologists better personalize treatment.

The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.

Significant volume growth for its Signatera minimal residual disease test helped boost the company's Q3 revenues.

The company has shifted its strategy to allow for multi-platform IVD adaptations of its current lab-developed tests, aiming to reach a broader diagnostics market.

The company is celebrating recent milestones for its MRD testing arm and its anticipated expansion into colorectal cancer screening.

The company's data, presented at a recent meeting and simultaneously published, showed performance results analogous to currently marketed tests.

The company reported that its Barrett's esophagus risk assay saw volumes more than triple in Q3 2023 compared to the same period last year.

The company recently shared positive results from its Blue-C study, intended to support an FDA approval bid for a second generation of its colon cancer screening test.

In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.

The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.